Spherix Global Insights Finds Benlysta Exposure Expanding and Rheumatologists Increasingly Turning to Lupkynis in Lupus Nephritis
A patient audit of more than 1,000 lupus nephritis charts highlights growing experience with biologics and calcineurin inhibitors, alongside rising off-label adoption of SGLT2 inhibitors.Exton, PA, March 06, 2026 (GLOBE NEWSWIRE) -- New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as specialists increasingly incorporate biologics, calcineurin inhibitors, and other targeted therapies into lupus nephriti
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.